Division 1: Colorectal, Anorectal & Pilonidal Disease

Guidelines 4

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

EAES-SAGES Clinical Practice Guideline Update: Multi-Society Recommendations on Key Controversies in the Management of Diverticular Disease

A multi-society update on the key controversies in diverticular disease: no routine antibiotics for uncomplicated diverticulitis, elective resection for persistent symptoms after recurrent episodes or recovery from a first abscess, and no routine follow-up colonoscopy after a first uncomplicated episode.

2026 Update · European Association for Endoscopic Surgery (EAES) and SAGES, with AAST, CSSANZ, EAST, ESCP, UEG and WSES participation

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer

The 2022 PSOGI consensus on HIPEC for colorectal peritoneal metastases: after complete cytoreductive surgery, HIPEC is conditionally recommended despite the negative PRODIGE-7 results — with short-duration high-dose oxaliplatin strongly rejected and mitomycin-C weakly favoured.

2022 Consensus · Peritoneal Surface Oncology Group International (PSOGI)

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases

The INDEPSO-ISPSM consensus on colorectal peritoneal metastases, written for Indian epidemiology and access: cytoreductive surgery for selected isolated or resectable disease, adjuvant systemic chemotherapy after CRS, and HIPEC outside trials only selectively — particularly at PCI 11–15.

2024 · Indian Network for Development of Peritoneal Surface Oncology (INDEPSO) and Indian Society of Peritoneal Surface Malignancies (ISPSM)

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

Multi-Society Guideline on Cytoreductive Surgery and HIPEC: Methodology and Overview of the Results

The multi-society CRS/HIPEC guideline's methodology and overview paper: seven recommendations built by GRADE ADOLOPMENT — conditional for metachronous colorectal and gastric peritoneal metastases, strong for pseudomyxoma, peritoneal mesothelioma and advanced ovarian cancer after neoadjuvant chemotherapy.

2024 · PSOGI with the European Society of Surgical Oncology, ERN-EURACAN, the Society of Surgical Oncology and partner societies (14 countries)

Live book 17

Candidate Shift — dMMR Colon Cancer: Neoadjuvant Immunotherapy Before Colectomy (§1.3 Trial 1.5)Test MMR/MSI on every colon biopsy, and route locally advanced dMMR colon cancer into a multidisciplinary pathway offering short-course neoadjuvant nivolumab + ipilimumab before colectomy.Candidate Shift — dMMR Rectal Cancer: Dostarlimab and Non-Operative Management (§1.3 Trial 1.6)In dMMR locally advanced rectal cancer, offer single-agent dostarlimab with non-operative watch-and-wait for clinical complete responders — only inside specialized multidisciplinary centers or clinical trials with intensive surveillance.Candidate Shift — ICG Fluorescence Perfusion Angiography as an Anastomotic Adjunct (§1.3 Trial 1.7)Use intraoperative indocyanine green (ICG) fluorescence perfusion angiography as an adjunct during minimally invasive rectal resection — it can change the transection line, but the two randomized trials disagree on leak reduction.Candidate Shift — Rectal Prolapse: Match the Approach to Fitness (Addendum Summary, Ch 1)Stratify rectal prolapse repair by fitness: laparoscopic ventral mesh or resection rectopexy for fit adults, perineal repair for the frail elderly.Candidate Shift — Sigmoid Volvulus & Ogilvie's: Decompress First, Then Definitive Treatment (Addendum Summary, Ch 1)Decompress non-gangrenous sigmoid volvulus endoscopically and resect in the same admission; treat refractory Ogilvie's syndrome with IV neostigmine or colonoscopic decompression.Practice Shift — Acute Pilonidal Abscess: Off-Midline Drainage, Risk-Based Antibiotics (Table 2.1)Drain an acute pilonidal abscess through an off-midline incision over the collection, and prescribe antibiotics by presentation and risk — not routinely for every drained abscess.Practice Shift — After Healing: Cleft Hygiene, Hair Control, and Selective Laser Epilation (Table 2.1)Counsel every pilonidal patient on gluteal cleft hygiene and hair control after healing — and consider adjunctive laser epilation in eligible adolescents and young adults, with the single trial's limits stated.Practice Shift — Chronic Anal Fissure: Topical Therapy Before Sphincterotomy (Table 1.1)Give topical vasodilators for 6–8 weeks first in chronic anal fissure; reserve sphincterotomy for low-risk medical failures.Practice Shift — Diverticulitis: Selective Antibiotic Omission, WSES Stage 0 Only (Table 1.1)Consider omitting antibiotics in strictly eligible WSES Stage 0 uncomplicated diverticulitis — and only there.Practice Shift — Fistula-in-Ano: Select by Continence Risk, Not a Sphincter Cutoff (Table 1.1)Choose fistula surgery by individual continence risk — never by a sphincter-percentage cutoff alone, and never divide the sphincter in complex tracts.Practice Shift — Hemorrhoids: Office-Based Therapy First (Table 1.1)Start with office rubber band ligation — not upfront excisional hemorrhoidectomy — for symptomatic Grade I–II and selected Grade III internal hemorrhoids.Practice Shift — Limited Pilonidal Disease: Shared Decision-Making, Not Wide Excision by Default (Table 2.1)In limited primary midline pilonidal disease, decide between minimally invasive and excisional surgery with the patient — match the choice to pit distribution, lateral extension, scarring and the recovery-versus-failure trade-off.Practice Shift — Perforated Diverticulitis (Hinchey III): Primary Anastomosis in Selected Patients (Table 1.1)In selected stable Hinchey III perforated diverticulitis, resect with primary anastomosis and a protective loop ileostomy instead of a routine Hartmann.Practice Shift — Pilonidal Reconstruction: Off-Midline Closure, Not Routine Midline Closure (Table 2.1)When pilonidal excision needs reconstruction, close off-midline (Karydakis, Bascom cleft lift, or Limberg/Dufourmentel) — not with a routine high-tension midline closure.Practice Shift — Stage II Colon Cancer: Universal MMR/MSI Testing, ctDNA-Informed Decisions (Table 1.1)Test every resected colon cancer for MMR/MSI, and use postoperative ctDNA to inform — never to settle — adjuvant decisions in Stage II disease.Stepwise Clinical Decision Pathway — Fistula-in-Ano (§1.2)Work the fistula pathway in five stages: exclude Crohn disease and tuberculosis first, map the tract, lay open only simple low fistulas, drain complex ones with a loose seton, then reconstruct sphincter-sparing.Stepwise Clinical Decision Pathway — Pilonidal Sinus Disease (§2.2)Work the pilonidal pathway in five stages: classify the phenotype first, drain abscesses off-midline with risk-based antibiotics, decide limited disease with the patient, reconstruct complex disease off-midline, and finish with wound care plus selective hair control.

Codes 75

EMR-APP-ALT-01 — Later appendicectomy after antibiotics-first29% at 90 days; 40% at 1 yr; 46% at 2 yrs; 49% at 3–4 yrs (appendicolith: 41% at 90 days vs 25% without)EMR-APP-COMP-01 — Superficial SSI1–3%EMR-APP-COMP-02 — Bleeding (requiring intervention, as worded to patients)<1% (0.2%)EMR-APP-COMP-03 — Organ/space SSI (intra-abdominal abscess)1–2%EMR-APP-COMP-04 — Postoperative ileusNo figure published — (qualitative)COL-PIL-REC-01 — RecurrenceCORRECTED 2026-11-06 — adopted from Stauffer's published table (merged RCT+non-RCT data): 3.4% at 12 m, 7.0% at 24 m, 16.8% at 60 m, 32.0% at 120 m — Recurrence after primary closure COL-PIL-REC-02 — Recurrence14.9% · 11% (95% CI 6–15) · ~11–15% with follow-up anchored (pooled ~11%; longest single-series follow-up 14.9%) — Recurrence after laser ablation COL-PIL-COMP-01 — Surgical site infectionhigher after midline closure: RR 3.72 (95% CI 1.86–7.42) · no significant SSI difference — SSI after excisional surgery COL-PIL-COMP-02 — SeromaDisputed — see D3. — Seroma formation after flap surgery COL-PIL-COMP-03 — Wound infection & dehiscenceNo significant difference — SSI / wound dehiscence after flap surgery COL-PIL-COMP-04 — Any complication7% (95% CI 1–15) — Overall postoperative complication rate COL-PIL-PREV-01 — Annual incidence~26 per 100,000 per year — New PSD cases per 100,000 population per year COL-PIL-PREV-02 — Sex distribution~4:1 male predominance — Male-to-female ratio of incident cases COL-PIL-REC-03 — Excision, left open (primary open healing)1.5% @12 m · 4.2% @24 m · 13.1% @60 m · 19.9% @120 m — (1.2–1.7) · (3.7–4.7) · (11.9–14.4) · (17.9–21.9)COL-PIL-REC-04 — Primary asymmetric (off-midline, non-flap) closure1.0% @12 m · 1.6% @24 m · 3.2% @60 m · 6.7% @120 m — (0.6–1.4) · (1.1–2.1) · (2.3–4.0) · (5.2–8.2)COL-PIL-REC-05 — Karydakis flap / Bascom cleft lift (grouped in the source)0.2% @12 m · 0.6% @24 m · 1.9% @60 m · 2.7% @120 m — (0.1–0.3) · (0.5–0.8) · (1.6–2.2) · (2.4–3.1)COL-PIL-REC-06 — Limberg / Dufourmentel flap0.4% @12 m · 1.6% @24 m · 5.2% @60 m · 11.4% @120 m — (0.3–0.5) · (1.3–1.9) · (4.5–5.8) · (9.2–13.7)COL-PIL-REC-07 — Phenol application (alone)1.9% @12 m · 14.1% @24 m · 40.4% @60 m — (1.1–2.6) · (11.8–16.5) · (27.8–52.9)COL-PIL-REC-08 — EPSiT (endoscopic treatment)9% (95% CI 5–12) — Pooled recurrence , mixed mostly short follow-up — Langenbecks SR/MA 2026, 10 EPSiT studies, single-arm pooling COL-PIL-REC-09 — Pit picking (incl. Bascom pit picking)2.7% @12 m · 6.5% @24 m · 15.6% @60 m — (2.2–3.1) · (5.7–7.3) · (13.8–17.4)COL-PIL-REC-10 — Incision & drainage alone (no definitive procedure)10.4% @12 m · 25.9% @24 m · 40.2% @60 m — (6.6–14.3) · (19.1–32.8) · (29.4–50.9)COL-PIL-RISK-01 — Family historyOR 4.31 — Positive family history of PSD COL-PIL-RISK-02 — Dense body hairOR 3.29 — Dense/coarse body hair (hirsutism)COL-PIL-RISK-03 — Infrequent bathingOR 3.36 — Bathing ≤2 times per week (hygiene proxy)COL-PIL-RISK-04 — Excess body weightOverweight OR 1.89; Obesity OR 2.05 — Overweight (BMI 25–29.9) / Obesity (BMI ≥30) vs normal weight COL-PIL-RISK-05 — Prolonged sittingNo pooled OR published in the MA — Sitting ≥6 h/day; occupational driving COL-PIL-RISK-06 — SmokingNo significant association — Smoking history COL-PIL-SUC-01 — EPSiT — cure (success) rate88% (95% CI 83–94) — Pooled cure , single-arm pooling of 10 studies; healing time mean 26.6 days (24.4–28.7)COL-PIL-TIME-01 — Return to work10.48 days earlier after primary closure — Days to return to work after surgery COL-PIL-TIME-02 — Complete healing timeEPSiT 26.6 days — (95% CI 24.4–28.7); SiLaC 30.1 days (25.9–38.2) — context COL-PIL-TIME-03 — Healing time difference5.4 days faster — Mean difference in days to healing COL-PIL-TIME-04 — Open-wound healing durationمؤقت (provisional): · 41–91 days · never headline this figure — Time for an excision wound left open to heal fully COL-ANA-ABS-PREV-01 — Abscess incidence20.2 per 100,000 population/year — First anorectal abscess incidence COL-ANA-ABS-PROG-01 — Abscess → fistula15.5% coded / 29.8% prospective; 67.5% within yr 1 — Idiopathic first abscess COL-ANA-ABS-RISK-01 — Fistula after abscess, by underlying disease41.6% (4,337/10,427) · 47.2% · 26.7% · 3.51 · 1.85 · 2.9% — IBD overall — Crohn's , ulcerative colitis ; idiopathic 15.5% (see dispute C8-i). Adjusted HRs for fistula: Crohn's (3.38–3.65), UC 1.82, female sex 1.18, age 41–60 (vs <20), intersphincteric site 1.53, ischiorectal site 1.48. Also: of «idiopathic» cases were later diagnosed with Crohn's (median 14 months)COL-ANA-ABS-SUCC-01 — Primary fistula surgery (fistulotomy/fistulectomy) at the time of abscess drainage vs drainage aloneRR 0.13 (0.07–0.24) · not significant — Recurrence / persistence / need for further surgery favouring primary fistula surgery; incontinence at 1 year RR 3.06 (0.70–13.45) — , wide CI, I²=44.4%COL-ANA-FIS-COMP-01 — Headache on GTN30% — During treatment course COL-ANA-FIS-COMP-02 — Continence disturbance after LISDispute — table B8. · 9.4% · 14% — See dispute table COL-ANA-FIS-PREV-01 — Fissure lifetime incidence~11% — Cumulative lifetime incidence COL-ANA-FIS-REC-01 — Late recurrence after GTN healing~50% — of fissures that initially heal on GTN recur late COL-ANA-FIS-SUCC-01 — Topical GTN 0.2–0.4%48.9% · 35.5% — healed vs placebo (p<0.0009)COL-ANA-FIS-SUCC-02 — Medical therapy pooled (network estimates)58.6% · 62.6% — Non-invasive topicals (GTN/CCB pooled) ; botulinum toxin injection COL-ANA-FIS-SUCC-03 — Lateral internal sphincterotomy (LIS)93.1% · ≈91.2% — (Ebinger, LIS-specific network estimate); concordant Cochrane pairwise: surgery non-healing 88/1000 → healing vs medical 467/1000 non-healing (15 studies, n=979)COL-ANA-FST-COMP-01 — Continence impairment after fistulotomy (simple fistula)any impairment 12.7% · major incontinence 6.0% — Pooled across 66-study review's sphincter-cutting arms COL-ANA-FST-POST-01 — Fistulotomy wound course41 days — Mean wound healing time ; mean operating time 21 minutes (simple fistula series within Litta)COL-ANA-FST-SUCC-01 — Fistulotomy for simple fistula93.7% · 14.7 months — Weighted healing (study range 61–100%), n=4,883, weighted mean follow-up — time-dispute table C8-ii COL-ANA-FST-SUCC-02 — Sphincter-sparing procedures for simple fistula (pooled within the same review)77.7% — Success (range 25–100%), n=602, mean FU 13.2 months; continence impairment ~0.2%COL-ANA-FST-SUCC-03 — Sphincter-sparing for complex/transsphincteric fistula (modern NMA)LIFT 71.4% · 74.1% · FiLaC 56.1% — Healing = 100 − failure: , endorectal advancement flap , VAAFT 77.7% (failure 22.3%), (failure 43.9%). Continence worsening: LIFT 1.5%, flap 7.3%, VAAFT 0%, FiLaC 0%. Minor complications: LIFT 4.3%, VAAFT 7.2%, FiLaC 10.2%, flap 6.2%. Crohn's fistulas fail more (39.5% vs 31.4%)COL-ANA-HEM-COMP-01 — Serious complications after RBL~1 in 100 — (2/187 randomised: 1 pain admission, 1 bleeding); older pooled narrative: RBL complications <2% overall COL-ANA-HEM-COMP-02 — Secondary haemorrhage needing hospital care1.4% (5/352) · 2.1% (7/338) · 0.6% (1/176) — Excisional any-bleeding SAE (bleeding alone 1; +pain 1; +constipation 2; +both 1); stapled ; RBL ; HAL ~1% (2/185, none transfused); transfusion needed in 2 of 690 eTHoS patients COL-ANA-HEM-COMP-03 — Urinary retention needing a catheter2.0% (7/352) — Excisional ; stapled 1.2% (4/338) — catheterisation SAEs COL-ANA-HEM-COMP-04 — Postoperative pain2.8% (10/352) — Admission for pain: excisional , stapled 1.8% (6/338). Pain scores (VAS 0–10): day 1 — RBL 3.4 vs HAL 4.6; day 7 — RBL 1.6 vs HAL 3.1; no difference by day 21 COL-ANA-HEM-COMP-05 — Anal stenosis≤1% — : eTHoS SAE stenosis — stapled 2/338 (0.6%), excisional 0/352; older pooled narrative ~1%COL-ANA-HEM-COMP-06 — Incontinence after excisional haemorrhoidectomy0.4% — in older pooled series; eTHoS continence scores *improved* after excisional surgery (mean CIS fell, p<0.0001)COL-ANA-HEM-PREV-01 — Haemorrhoid prevalence (point)25.9% — Pooled point prevalence (95% CI 22.6–29.2); 1-year prevalence 21.7%; lifetime 27.2%; women 27.3%; examination-based methods 28.1%COL-ANA-HEM-RISK-01 — Chronic constipation/straining, low-fibre diet, prolonged sitting, pregnancy, obesity, ageingQualitative. · not · not used — In Riss 2012's multivariate analysis BMI was significantly associated with haemorrhoids (p≈0.03–0.04); no defensible pooled rate per factor was found in the sources opened. A «+3.5% risk per BMI point» figure circulating in secondary summaries could be verified against the primary paper and is (see integration block).COL-ANA-HEM-SUCC-01 — Rubber band ligation (RBL), grade II–IIIsingle · 49.4% (87/176) · course · 37.5% — Recurrence after a banding session vs HAL 29.8% (48/161); adjusted OR 2.23 (1.42–3.51), p=0.0005. Recurrence after a of RBL (repeat banding allowed): vs 30.0%, aOR 1.35, p=0.20 (NS). 18% needed a second banding; further procedure 32% vs 14%COL-ANA-HEM-SUCC-02 — Haemorrhoidal artery ligation (HAL)29.8% (48/161) — Recurrence at 1 year; serious adverse events 12/185 (6.5%): pain 5, bleeding 2, urinary retention 2, vasovagal 2, possible sepsis 1 COL-ANA-HEM-SUCC-03 — Excisional haemorrhoidectomy (TES) vs stapled haemorrhoidopexy (SH)Patient-reported recurrence: · 14.0% (39/278) · 25.3% (76/300) · Trial-examined recurrence (Cochrane): · 1.9% (9/476) · 7.7% (37/479) — 12 mo — TES vs SH 31.9% (94/295); 24 mo — TES vs SH 42.3% (134/317), OR 2.25 (1.46–3.46). Further surgery by 24 mo: TES 6.2% vs SH 9.3% (p=0.11, NS). conventional vs stapled , OR 3.22 (1.59–6.51)RSK-CRC-FH-01 — RR, ≥1 FDR with CRC≥1 FDR with CRC: RR 2.24 — (95% CI 2.06–2.43)RSK-CRC-FH-02 — RR, ≥2 FDRs≥2 FDRs with CRC: RR 3.97 — (2.60–6.06)RSK-CRC-FH-03 — RR by relative's age at dxBy the relative's age at diagnosis: · <50 y: RR 3.55 · ≥50 y: RR 2.18 · not significant · 3.87 — diagnosed (1.84–6.83) · (1.56–3.04) — difference (P=0.19). By the at-risk person's own age: RR 3.17 (2.37–4.25) if the person is <50 vs 1.90 (1.59–2.28) if ≥50 (P=0.003). Johns & Houlston gradient: index <45 y (2.40–6.22) · 45–59 y 2.25 (1.85–2.72) · ≥60 y 1.82 (1.47–2.25)RSK-CRC-FH-04 — Absolute risk translationsAbsolute translations (never quote the RR alone): · by age 70 · 2.0% · 3.6% · 7.4% · 50-year-old · 3.4% · 6.9% · by age 79 — Butterworth lifetables (England & Wales 2001 baseline) — risk of CRC : general population (1 in 50) · ≥1 FDR (1 in 30) · ≥2 FDRs (1 in 14). Remaining lifetime risk for a : 1.8% → (2.8–4.0) with ≥1 FDR → (4.5–10.4) with ≥2. NCI PDQ translation (US baseline, risk ): no FH 4% · 1 FDR 9% · >1 FDR 16% · FDR diagnosed <45 y 15% · FDR with adenoma 8%RSK-CRC-FH-05 — Adenoma in FDR → CRCAdenoma in an FDR: · 1.99 — RR of CRC (1.55–2.55) (9 studies)RSK-CRC-FH-06 — Lynch share of new CRC~1–3% of newly diagnosed CRC cases — MMR pathogenic variants account for (multiple large population-based series, as summarised by the guideline)RSK-CRC-FH-07 — Lynch population frequency~1 in 300 individuals — Lynch syndrome population frequency: («the most common hereditary cancer syndrome»)RSK-CRC-FH-08 — Lynch CRC risk by gene @75CRC cumulative incidence to age 75, by gene and sex (PLSD 2023 update — standing set since adjudication 2026-11-08): · 48.3% · 56.0% · 42.6% · 55.8% · 17.3% · 16.4% · 8.5% · 32.8% — MLH1 — F , M · MSH2 — F , M · MSH6 — F , M · PMS2 — F , M (full sex split now published, incl. PMS2). Superseded PLSD 2020 set (n=6,350, with CIs and age-50 detail) preserved in dispute tables B8-i/B8-ii as history only RSK-CRC-FH-09 — Lynch endometrial @75Endometrial cancer cumulative incidence to age 75 (PLSD 2023 update — standing set since Tamer's decision 2026-11-09, unifying with FH-08): · 37.2% · 44.1% · 45.7% · 21.2% — MLH1 · MSH2 · MSH6 · PMS2 — in women, gynaecological cancers rival or exceed CRC in MSH2/MSH6/PMS2 carriers. Superseded PLSD 2020 set (37.0 / 48.9 / 41.1 / 12.8) preserved in the registry's B8 adjudication note of 2026-11-09 as history only RSK-CRC-FH-10 — Mean age CRC, Lynch vs sporadic44–61 years · 69 years — Mean age at CRC diagnosis in Lynch syndrome: (gene-dependent) vs in sporadic CRC RSK-CRC-FH-11 — Surveillance benefit (Lynch)Surveillance works (historical controlled cohort): · 62% reduction in CRC incidence · 65% less CRC death — colonoscopic surveillance in Lynch families — and (P=0.003) vs those who declined surveillance (Järvinen programme, as summarised and tabulated by ACG)RSK-CRC-FH-12 — FAP untreated CRC risk~100% · 38–41 years · 39 years (range 34–43) · 69% — Untreated classic FAP: CRC risk ; average age at CRC (guideline table); GeneReviews-derived mean age ; ~95% have polyps by age 35. Attenuated FAP: CRC risk , average age 54–58 RSK-CRC-FH-13 — FAP prevalence1 in 6,850 to 1 in 31,250 live births · ≤0.5–1% — FAP prevalence: (a wide, honestly-reported range); FAP accounts for of all CRC RSK-CRC-FH-14 — ACG CRC Screening 2021 (family-history arm)ACG FH screening: @40 or −10 y, q5y — ACG CRC Screening 2021 (family-history arm): 1 FDR with CRC or advanced adenoma diagnosed <60 y, or ≥2 FDRs at any age → colonoscopy at age 40 or 10 years before the youngest case, whichever is earlier, repeated every 5 years. 1 FDR diagnosed ≥60 y → start screening at 40 (any modality), then average-risk intervals if normal. Only 1 second-degree relative → average-risk screening. (US Multi-Society Task Force position is concordant.)RSK-CRC-FH-15 — Lynch surveillance (ACG Hereditary 2015)Lynch surveillance: ≥q2y from 20–25 — Lynch surveillance (ACG Hereditary 2015): colonoscopy at least every 2 years beginning age 20–25; annual colonoscopy should be considered in confirmed carriers; for MSH6/PMS2 carriers, starting at 25–30 may be considered unless an early-onset family cancer dictates earlier RSK-CRC-FH-16 — FAP surveillance (ACG Hereditary 2015)FAP surveillance: annual from puberty — FAP surveillance (ACG Hereditary 2015): annual colonoscopy or flexible sigmoidoscopy beginning at puberty for at-risk/affected individuals in classic FAP families; absolute colectomy indications = documented/suspected cancer or significant symptoms

Memory 10

FOLFOXColorectal cancer chemotherapy regimen (acronym-device)FOLFIRIColorectal cancer chemotherapy regimen (acronym-device)Goodsall's rulePredicting anal fistula tract course (a rule, not an acronym)MANTRELSAlvarado score for acute appendicitis (score-as-mnemonic)MAFLTRNModified Alvarado score (/9) — "My Appendix Feels Likely To Rupture Now"DRAINCauses of lower GI bleeding FITColorectal cancer screening (name-device)FAPFamilial Adenomatous Polyposis — the syndrome acronym NERDSSuperficial wound infection / critical colonisation STONEESDeep / surrounding wound infection (the STONEES pair of NERDS)